Jubilant Biosys Announces Successful Achievement of an Early Milestone Related to One of Their Collaborative Discovery Programs

Food and Healthcare Press Releases Wednesday November 29, 2017 17:59
BENGALURU--29 Nov--PRNewswire/InfoQuest

Jubilant Biosys Ltd. , a Bengaluru-based subsidiary of Jubilant Life Sciences Ltd., announced today that they successfully achieved an early-stage milestone related to a collaborative program with Sanofi in Frankfurt, Germany focused on metabolic disorders. The milestone reflects the successful transition of a collaborative program to the next phase in the discovery and development process.

(Logo: http://photos.prnewswire.com/prnh/20160107/783587 )

This alliance is part of a portfolio of programs, which began in 2016, focused on the   discovery and development of small molecule inhibitors for multiple targets designed to address the unmet medical needs in diabetes and obesity. Jubilant Biosys confirmed receiving payment for the first milestone achievement for this collaboration. Jubilant Biosys will continue to apply its effective integrated drug discovery platform to generate novel molecules that can demonstrate clinical proof-of-mechanism.

"Jubilant Biosys has invested in its metabolic disease platform to enable the discovery and development of small molecule therapeutics. Since inception of this collaboration, the teams at Jubilant Biosys and Sanofi have worked closely on several first-in-class metabolic disease programs. We look forward to advancing these programs further through the discovery and development process to deliver important new therapeutics to treat diabetes," said Mr. Steven Hutchins, Jubilant Biosys, President, Drug Discovery Solutions.

Dr. Philip Just Larsen, Global Head of Diabetes Research & Chief Scientific Officer, Sanofi, Germany, said: "Sanofi works on continuously innovating to deliver value for people living with metabolic disorders. This productive collaboration with Jubilant Biosys further illustrates our commitment to discover and develop new therapies to support patients with diabetes or its complications."

About Jubilant Biosys Limited

Jubilant Biosys a subsidiary of Jubilant Life sciences Ltd, an integrated global pharmaceutical and life sciences company, has presence in Bengaluru and Noida in India. Jubilant Biosys has demonstrated expertise in multiple therapeutic areas including but not limited to Oncology, Metabolic Disorders, Pain & Inflammation and CNS. The business model includes drug discovery services, proprietary in-house innovation and strategic investments as the core components which are available for collaborative research, partnership and out-licensing.

For more info: http://www.jubilantbiosys.com ; http://www.jubl.com
For Business Development:
Dr. Rajiv Tyagi
Tel: +91-80-66628400
Email: Rajiv_Tyagi@jubilantbiosys.com
Source: Jubilant Biosys

Latest Press Release

Walgreens Boots Alliance and Microsoft establish strategic partnership to transform health care delivery

- Companies aim to improve health outcomes and lower overall costs with enhanced digital and retail experiences and an R&D commitment to build health care solutions through seven-year agreement Walgreens Boots Alliance Inc. (WBA) and Microsoft Corp....

Ascensia Diabetes Care Announces Global Partnership With POCTech to Distribute and Co-develop Continuous Glucose Monitoring Systems

Ascensia Diabetes Care today announced it has entered into a global alliance with Zhejiang POCTech, Co., Ltd (POCTech), a developer and manufacturer of continuous glucose monitoring (CGM) systems. (Logo:...

MGI Announces Milestone of 1,000 Sequencers Installed and Opens Early Access Program for Groundbreaking Ultra-High-Throughput Sequencer, MGISEQ-T7

MGI, established in 2016 as a subsidiary of global genomics leader BGI Group, announced it has reached a new milestone of 1,000 MGI sequencers installed in 16 countries. MGI Chief Operating Officer Dr. Hui Jiang also announced the availability of MGI's...

Gift of Life Donor Program is U.S. Leader in Saving Lives

For the 11th consecutive year, Gift of Life Donor Program is the nation's leading organ procurement organization (OPO), coordinating the most life-saving organs for transplant among all 58 U.S. OPOs. Gift of Life broke two national records in 2018,...

Helsinn Group Grants Exclusive Licensing Rights to Menarini for Pracinostat

Licensing rights are worldwide excluding US, Canada, Japan and South AmericaHelsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and Menarini, an Italian biopharmaceutical Group active in 136 countries worldwide, today...

Related Topics